Beijing Tiantan Biological Products | Sustainability Performance
Develops, manufactures, and distributes vaccines and blood-derived biopharmaceutical products.
1998
China
5,001 - 10,000 employees
Biotechnology
$500M - 1B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#9326
Overallⓘ#568
in Chinaⓘ#212
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Nature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG Impact
Critical
Leading
Controversy level
- Beijing Tiantan Biological Products Corp (Shanghai-listed 600161.SH, Chinese state-affiliated blood products major, China National Biotec Group (CNBG) / Sinopharm-affiliated dominant Chinese human albumin and immunoglobulin maker) has faced sustained scrutiny over Chinese blood plasma collection sector customer compliance practices (the Chinese plasma sector carries the historic 1990s Henan contaminated plasma collection HIV scandal legacy driving sustained NHC plasma station licensing scrutiny), plus sustained scrutiny over Sinopharm/CNBG state-affiliated controlling shareholder governance complexity affecting Tiantan Biological institutional minority shareholders amid Chinese blood products sector regulatory pressure.
